Keywords: topotargets, initiates, ph, ii, savicol, trial, fap

TopoTargets initiates Ph II Savicol trial for FAP

Article | 20 February 2006

Print This

Denmark's TopoTarget A/S has commenced patient treatment in a pivotal Phase II study of Savicol, a histone deacetylase (HDAC) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in